Clinical efficacy of
Cefmetazole was evaluated at four university hospitals and their related hospitals in Nagoya. For the treatment of
urinary tract infections with or without complications, 177 patients were administered
Cefmetazole. Of these patients, 69 had chronic complicated
urinary tract infection defined in the UTI manual and 20 had simple acute
pyelonephritis. The other urological
infections for which
Cefmetazole was administered included
prostatitis,
epididymitis, urosepsis and
wound infections. Fifty four patients were given
Cefmetazole intravenously after urological operation to prevent
wound and
urinary tract infections. The overall clinical efficacy of
Cefmetazole for UTI was 76.8%; 84.4% for group 1, 85.7% for group 3, 75% for group 4, 44.4% for group 5 and 66.6% for group 6. In acute
pyelonephritis due to E. coli, Klebsiella, Serratia, S. aureus, alpha-Streptococcus and S. epidermidis all patients were cured by
Cefmetazole administration. Clinical efficacy of
Cefmetazole was assessed to be excellent in 6 cases of
prostatitis and 6 cases of acute
epididymitis. E. Coli, Serratia and some organisms disappeared from blood after the administration of
Cefmetazole but Pseudomonas persisted even
after treatment. Postoperative administration of
Cefmetazole was effective for eradication of bacteria from the urine in 26 out of 30 patients and in prevention of
infection in 24 cases. After the administration of
Cefmetazole skin eruption was observed in one patient and
nausea in another. Slight elevation of GOT, GPT and total
bilirubin was noted in 3 of the 177 patients after medication.